ADAVOSERTIB HEMIHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C27H32N8O2.H2O
Molecular Weight	1019.206
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C4=N3)C5=NC(=CC=C5)C(C)(C)O)C=C2.CN6CCN(CC6)C7=CC=C(NC8=NC=C9C(=O)N(CC=C)N(C9=N8)C%10=NC(=CC=C%10)C(C)(C)O)C=C7

InChI

InChIKey=BMQMRZXQRFUQIR-UHFFFAOYSA-N

InChI=1S/2C27H32N8O2.H2O/c2*1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37;/h2*5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31);1H2

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24013427
Curator's Comment: description was created based on several sources, including: https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=594147 | http://adisinsight.springer.com/drugs/800028808 | https://ncats.nih.gov/files/AZD1775.pdf

AZD1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Current ongoing trials of AZD1775 include monotherapy and combination therapy with certain DNA damaging agents in solid tumors, ovarian tumors, gynaecological cancer, non-small cell lung cancer. AZD1775 is genotoxic, which is considered to be a result of its mechanism of action. Common serious adverse events (with chemotherapy) include: febrile neutropenia, neutropenia, thrombocytopenia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serine/threonine-protein kinase WEE1 3 Target ID: CHEMBL5491 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19887545	Inhibitor 8297		5.2 nM [IC50]
Tyrosine-protein kinase YES 4 Target ID: CHEMBL2073 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19887545	Inhibitor 8297		14.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Ovarian cancer 157 Sources: https://ncats.nih.gov/files/AZD1775.pdf http://adisinsight.springer.com/drugs/800028808	Primary	Phase II 1132	Unknown Approved Use Unknown
Non-small cell lung cancer 206 Sources: http://adisinsight.springer.com/drugs/800028808	Primary	Phase II 1132	Unknown Approved Use Unknown
Adenocarcinoma of the pancreas 2 Sources: https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2014-01214&r=1	Primary	Phase II 1132	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	Other AEs: vomiting, fatigue... Other AEs: vomiting (grade 2, 2 patients) fatigue (grade 2, 1 pt) anemia (grade 3, 1 pt) hyponatremia (grade 3, 1 pt) thrombocytopenia (grade 3, 2 patients) nausea (grade 3, 2 patients) Leukopenia (grade 4, 1 pt) neutropenia (grade 4, 5 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
400 mg 1 times / day multiple, oral (starting) Studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 3 Health Status: unhealthy Condition: solid tumour Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	DLT: neutropenia, Pancytopenia... Dose limiting toxicities: neutropenia (grade 4, 1 pt) Pancytopenia (grade 4, 1 pt) Fatigue (grade 3, 1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	Other AEs: Neutropenia, Lymphopenia... Other AEs: Neutropenia (grade 3, 2 patients) Lymphopenia (grade 3, 1 pt) Thrombocytopenia (grade 3, 1 pt) anemia (grade 3, 1 pt) Leucopenia (grade 3, 1 pt) Nausea (grade 3, 1 pt) Diarrhea (grade 3, 1 pt) Hypophosphatemia (grade 3, 1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
300 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 3 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	DLT: Myelosuppression, Supraventricular tachyarrhythmia... Dose limiting toxicities: Myelosuppression (grade 4, 1 pt) Supraventricular tachyarrhythmia (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/25964244

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461	OATP1A2 62 OATP2B1 104 OAT3 339 P-gp 1537 BCRP 561

Drug as perpetrator

Target	Modality	Activity
CYP2C9 1819	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=363677250	inconclusive [IC50 18.9991 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=363677250	no
CYP3A4 1925	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=363677250	no
P-gp 1650	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=137276027	yes [IC50 3.7221 uM]

Drug as victim

Target	Modality	Activity
OAT3 339	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28928160/	no
OATP2B1 104	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28928160/	no
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29147815/	yes
OATP1A2 62	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28928160/	yes
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29147815/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY116012	https://www.001chemical.com/chem/search?q=DY116012
1PlusChem LLC	1P003AL1	https://www.1pchem.com/search?query=1P003AL1
A2B Chem	AB52885	http://a2bchem.com/prod/AB52885
AChemBlock	M15123	http://www.achemblock.com/catalogsearch/result/?q=M15123
AK Scientific	SYN5698	https://aksci.com/item_detail.php?cat=SYN5698
AK Scientific	X7493	https://aksci.com/item_detail.php?cat=X7493
AOBIOUS INC	AOB87173	http://aobious.com/aobious/search?search_query=AOB87173
Ambeed	A399066	http://www.ambeed.com/search/Search.html?keyword=A399066
Angene	AGN-PC-0WH8XO	http://www.angenechemical.com/productshow/AGN-PC-0WH8XO.html
ApexBio Technology	A5755	https://www.apexbt.com/catalogsearch/result/?q=A5755
AstaTech	27926	http://astatechinc.com/CPSResult.php?CRNO=27926
Axon MedChem	1494	https://www.axonmedchem.com/product/1494
Cayman Chemical	21266	http://www.caymanchem.com/app/template/Product.vm/catalog/21266
Chem Scene	CS-0105	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0105
ChemShuttle	101254	https://www.chemshuttle.com/catalogsearch/result/?q=101254
Combi-Blocks	QJ-1903	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-1903
Excenen	EX-A331	http://www.excenen.com/searchresultlist.php?id=EX-A331
Hairui	HR106075	http://www.hairuichem.com/en/product/search.do?q=HR106075
KeyOrganics	AS-17001	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-17001
Lab Seeker	SC-94519	http://www.labseeker.com/search.php?keywords=SC-94519&category=0
LabSeeker	SC-94519	http://www.labseeker.com/search.php?keywords=SC-94519&category=0
Matrix Scientific	120722	http://www.matrixscientific.com/120722.html
MedChem Express	HY-10993	https://www.medchemexpress.com/search.html?q=HY-10993&ft=&fa=&fp=
MolPort	MolPort-016-633-227	https://www.molport.com/shop/molecule-link/MolPort-016-633-227
Molcore	MC116012	http://www.molcore.com/CatMC116012.html
Molnova	M16820	https://www.molnova.com/en/serch-list.html?keywords=M16820
MuseChem	I005658	https://www.musechem.com/product/I005658.html
PI Chemicals	PI-38309	http://www.pipharm.com/catalog_products/PI-38309.html
Ryan Scientific	Mirabegron	https://ryansci.com/products?q=Mirabegron&list_q=&search_type=exact
ShangHai Biochempartner	BCP000191	http://www.biochempartner.com/search_BCP000191
ShangHai Biochempartner	BCP01928	http://www.biochempartner.com/search_BCP01928
TargetMol	T2077	https://www.targetmol.com/search?keyword=T2077
eMolecules	36000452	https://orderbb.emolecules.com/search/#?query=36000452
eNovation Chemicals	D572857	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D572857&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-8668868093	https://mcule.com/MCULE-8668868093/

PubMed

Title	Date	PubMed
		252160193

Patents

Sample Use Guides

In Vivo Use Guide

The starting dose was 225 mg twice per day over 2.5 days for 1 week of a 21-day cycle. With subsequent dose escalations, at 225 mg or 300 mg twice per day for 2.5 days per week for 2 consecutive weeks of a 21-day cycle.

Route of Administration: Oral

In Vitro Use Guide

AZD1775 inhibits Wee1 activity and induces DNA damage as well as G2 checkpoint escape in cell-based assays with an EC50 of about 80 nM.

Name

Type

Language

ADAVOSERTIB HEMIHYDRATE

Common Name

English

3H-PYRAZOLO(3,4-D)PYRIMIDIN-3-ONE, 1,2-DIHYDRO-1-(6-(1-HYDROXY-1-METHYLETHYL)-2-PYRIDINYL)-6-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-2-(2-PROPEN-1-YL)-, HYDRATE (2:1)

Systematic Name

English

MK-1775 HEMIHYDRATE

Code

English

Code System Code Type Description

CAS

1277170-60-1

Created by admin on Fri Dec 15 17:39:57 GMT 2023 , Edited by admin on Fri Dec 15 17:39:57 GMT 2023

PRIMARY

PUBCHEM

50992433

Created by admin on Fri Dec 15 17:39:57 GMT 2023 , Edited by admin on Fri Dec 15 17:39:57 GMT 2023

PRIMARY

FDA UNII

NDV91627P9

Created by admin on Fri Dec 15 17:39:57 GMT 2023 , Edited by admin on Fri Dec 15 17:39:57 GMT 2023

PRIMARY

SMS_ID

300000014641

Created by admin on Fri Dec 15 17:39:57 GMT 2023 , Edited by admin on Fri Dec 15 17:39:57 GMT 2023

PRIMARY

ACTIVE MOIETY


					K2T6HJX3I3

ADAVOSERTIB

SUBSTANCE RECORD


					NDV91627P9

ADAVOSERTIB HEMIHYDRATE

AE	Significance	Dose	Population
fatigue	grade 2, 1 pt	300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
vomiting	grade 2, 2 patients	300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
anemia	grade 3, 1 pt	300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
hyponatremia	grade 3, 1 pt	300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
nausea	grade 3, 2 patients	300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
thrombocytopenia	grade 3, 2 patients	300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
Leukopenia	grade 4, 1 pt	300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
neutropenia	grade 4, 5 patients	300 mg 1 times / day multiple, oral (starting) MTD Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 6 Health Status: unhealthy Condition: solid tumor Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
Fatigue	grade 3, 1 pt DLT	400 mg 1 times / day multiple, oral (starting) Studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 3 Health Status: unhealthy Condition: solid tumour Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
Pancytopenia	grade 4, 1 pt DLT	400 mg 1 times / day multiple, oral (starting) Studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 3 Health Status: unhealthy Condition: solid tumour Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
neutropenia	grade 4, 1 pt DLT	400 mg 1 times / day multiple, oral (starting) Studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33863809	unhealthy, ADULT n = 3 Health Status: unhealthy Condition: solid tumour Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/33863809
Diarrhea	grade 3, 1 pt	225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
Hypophosphatemia	grade 3, 1 pt	225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
Leucopenia	grade 3, 1 pt	225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
Lymphopenia	grade 3, 1 pt	225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
Nausea	grade 3, 1 pt	225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
Thrombocytopenia	grade 3, 1 pt	225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
anemia	grade 3, 1 pt	225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
Neutropenia	grade 3, 2 patients	225 mg 2 times / day multiple, oral (unknown) MTD Dose: 225 mg, 2 times / day Route: oral Route: multiple Dose: 225 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 19 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 19 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
Supraventricular tachyarrhythmia	1 pt DLT, Disc. AE	300 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 3 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244
Myelosuppression	grade 4, 1 pt DLT, Disc. AE	300 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25964244	unhealthy n = 3 Health Status: unhealthy Condition: solid tumors Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/25964244

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Drug as perpetrator